Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
Novel FLT3 inhibitors may be considered to treat hyperdiploid or relapsed ALL
August 6th, 2004
Novel FLT3 inhibitors may be considered for the treatment of hyperdiploid or relapsed acute lymphoblastic leukemia. "Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML) but are rare in adult acute lymphoblastic leukemia (ALL). "We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Because hyperdiploid ALL samples also show high-level expression of FLT3, we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL," researchers in the United States report. ...
Source: Genomics & Genetics Weekly (2004-08-06)
|
